Trial Designed to Demonstrate Target Engagement, Safety, and Pharmacokinetics CLEVELAND, April 7, 2026 /PRNewswire/ -- NeuroTherapia, Inc., a clinical-stage company focused on developing oral ...
Opinion
2dOpinion
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Replimune disagrees with the FDA about whether the data set, upon which breakthrough therapy designation was awarded, is sufficient to allow this promising medicine to be made available to advanced ...
In what is believed to be the first randomized placebo-controlled trial of its kind, patients with a chronic total blockage ...
Late breaking results from the phase III NRG GY019 trial indicate that letrozole monotherapy (L) did not demonstrate non ...
Dr. Jennifer Buell (President, CEO & Director) reiterated MiNK’s differentiation as “an off the shelf” allogeneic iNKT platform that is “administered without lymphodepletion, without HLA matching,” ...
While recent FDA guidance speaks to the agency’s support of innovative trial designs—including the use of external ...
Organogenesis Holdings Inc. looks undervalued at distressed multiples; new DFU RCT data supports coverage despite 2026 CMS ...
The largest analysis of psychedelic brain imaging to date offers a clearer picture of how psychedelic drugs affect the brain.
In what is believed to be the first randomized placebo-controlled trial of its kind, patients with a chronic total blockage of a coronary artery who received a nonsurgical procedure to reopen the ...
Ten years after tailored radiotherapy (RT) for breast cancer, fewer than 3% of patients had locoregional recurrences (LRR), ...
A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission – IRVINE, Calif., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results